Product Name:

LATS1-pS909


Product Number:

ab-pk678

Price:

Regular price
$89.00
Regular price
Sale price
$89.00

Download Product PDF

Target Full Name: Large tumour suppressor 1 protein-serine kinase (WARTS)

Target Alias: Large tumour suppressor 1; LATS, large tumour suppressor, 1; WARTS; wts; ENSG00000131023

Product Type Specific: Protein kinase phosphosite-specific antibody

Antibody Code: PK678

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: S909

Protein UniProt: O95835

Protein SigNET: O95835

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human LATS1 sequence peptide Cat. No.: PE-04ANH99

Antibody Immunogen Sequence: LAH(pS)LVG(bA)C

Antibody Immunogen Description: Corresponds to amino acid residues L906 to G912; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.

Production Method: Corresponds to amino acid residues L906 to G912; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.

Antibody Modification: Protein kinase phosphosite-specific antibody

Antibody Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Very weak immunoreactivity of a target-sized protein by Western blotting in MCF7 cells. Very strong immunoreactivity with immunogen peptide on dot blots.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 140-170 kDa.

Antibody Specificity: Very high

Antibody Cross Reactivity: No significant cross-reactivities in HeLa and MCF7 cells or in sea star oocytes.

Scientific Background: LATS1 (WARTS) is a protein-serine/threonine kinase of the AGC group and NDR family. LATS1 appears to be a tumour suppressor protein (TSP), although it undergoes a typical rate of bystander mutations in human cancers. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It also promotes apoptosis by activating the transcription of BAX, caspase 3 and p53, and inhibiting the oncogene actions of YAP1. It can phosphorylate and inactivate the YAP1 and inhibit its translocation to the nucleus for transcription of genes important for proliferation and migration. NUAK1 and NUAK2 mediated phosphorylation of LATS1 can be inhibited with a LATS1 mutation of S464A. Inhibition of LATS1-YAP1 interaction can occur with a Y559F mutation. The K734A mutation can abrogate kinase phosphotransferase activity, lack of p53 translation, increased time for mitosis, autophosphorylation, and increased ploidy. LATS1 also negatively regulates the G2/M transition by downregulating CDK1 phosphotransferase activity. M669I and R806P mutations have been associated with lung adenocarcinoma and lung large cell carcinoma, respectively. Decreased LATS1 expression due to hypermethylation of the promoter have been associated with breast cancer, acute lymphoblastic leukemia, ovarian cancer, and astrocytoma. However, the very low frequency of reported somatic mutations in this protein indicates that it may function as a tumour requiring protein (TRP) in many human tumours. LATS1 is activated by phosphorylation at S909 and T1079.